Short Interest in Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Decreases By 72.9%

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 169,677 shares, a decline of 72.9% from the May 31st total of 625,772 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average daily trading volume, of 2,555,159 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Jupiter Neurosciences currently has an average rating of “Sell”.

Hedge Funds Weigh In On Jupiter Neurosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in JUNS. Geode Capital Management LLC increased its position in shares of Jupiter Neurosciences by 27.8% in the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after buying an additional 28,826 shares in the last quarter. Allen Capital Group LLC bought a new position in Jupiter Neurosciences during the fourth quarter worth about $31,000. Yorkville Advisors Global LP acquired a new position in Jupiter Neurosciences in the fourth quarter valued at about $135,000. Finally, Vestor Capital LLC grew its stake in Jupiter Neurosciences by 144,607.2% in the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after acquiring an additional 970,314 shares during the period.

Jupiter Neurosciences Stock Performance

NASDAQ:JUNS traded down $0.07 during mid-day trading on Monday, hitting $0.21. The company had a trading volume of 3,540,822 shares, compared to its average volume of 3,725,554. Jupiter Neurosciences has a fifty-two week low of $0.17 and a fifty-two week high of $3.33. The firm has a market cap of $7.62 million, a P/E ratio of -0.78 and a beta of 1.72. The business’s fifty day moving average is $0.30 and its two-hundred day moving average is $0.55.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.23 million.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.